Chemistry:Tozadenant
From HandWiki
Tozadenant (INN, USAN; developmental code names RO4494351 and SYN-115) is an adenosine A2A receptor antagonist which was under development for the treatment of Parkinson's disease and liver disorders but was never marketed due to safety concerns.[1][2] It is taken orally.[1] Tozadenant was under development by Roche, Acorda Therapeutics, and Biotie Therapies.[1] It reached phase 3 clinical trials for Parkinson's disease prior to the discontinuation of its development.[1] The development of tozadenant was discontinued due to findings of agranulocytosis and associated serious adverse effects in clinical trials including five patient deaths.[1][3][4]
See also
- Adenosine receptor antagonist
- List of investigational Parkinson's disease drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Acorda Therapeutics". 5 November 2023. https://adisinsight.springer.com/drugs/800025585.
- ↑ "Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant". Expert Opinion on Pharmacotherapy 15 (8): 1097–1107. June 2014. doi:10.1517/14656566.2014.903924. PMID 24673462.
- ↑ "Acorda slumps on safety fears for Parkinson's drug tozadenant". 15 November 2017. https://www.fiercebiotech.com/biotech/acorda-slumps-safety-fears-for-parkinson-s-drug-tozadenant.
- ↑ "Acorda dumps $363M Parkinson's drug after patient deaths". 20 November 2017. https://www.fiercebiotech.com/biotech/acorda-dumps-363m-parkinson-s-drug-after-patient-deaths.
 |  |
